APLS - Apellis Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

4.494B

Cash

333.5M

Avg Qtr Burn

-137.5M

Short % of Float

18.57%

Insider Ownership

14.32%

Institutional Own.

94.47%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SYFOVRE™(Intravitreal pegcetacoplan) Details Age-related macular degeneration, Geographic atrophy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Empaveli (systemic pegcetacoplan) (APL-2) Details Paroxysmal nocturnal hemoglobinuria	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details C3 Glomerulopathy, Immune complex membranoproliferative glomerulonephritis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Hematopoietic stem cell transplantation thrombotic microangiopathies	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APL-3007 (small interfering RNA silencing C3) Details Autoimmune disease, Inflammatory disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Amyotrophic lateral sclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intravenous APL-9 Details ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Systemic pegcetacoplan (APL-2) Details Cold agglutinin disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.